Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating)’s stock price was up 5.7% on Tuesday . The stock traded as high as $10.24 and last traded at $10.20. Approximately 213,544 shares were traded during trading, a decline of 65% from the average daily volume of 606,648 shares. The stock had previously closed at $9.65. Wall Street […]
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) shares hit a new 52-week high on Friday . The stock traded as high as $10.06 and last traded at $10.06, with a volume of 635541 shares. The stock had previously closed at $9.13. Analysts Set New Price Targets A number of research firms have recently issued reports […]
Opaleye Management Inc. bought a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 826,200 shares of the biopharmaceutical company’s stock, valued at approximately $3,288,000. Marinus Pharmaceuticals makes up approximately 1.1% of […]
StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a research report report published on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on MRNS. Royal Bank of Canada reduced their price objective on Marinus Pharmaceuticals from $23.00 to $22.00 […]
StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. MRNS has been the subject of a number of other reports. SVB Leerink reduced their price objective on shares of Marinus Pharmaceuticals from […]